Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196


Indacaterol therapy in patients with COPD not receiving other maintenance treatment.

Decramer M, Rossi A, Lawrence D, McBryan D.

Respir Med. 2012 Dec;106(12):1706-14. doi: 10.1016/j.rmed.2012.08.022. Epub 2012 Sep 29. Review. Erratum in: Respir Med. 2013 Jan;107(1):160. Dosage error in article text.


Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.


Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.

Respir Med. 2013 Feb;107(2):223-32. doi: 10.1016/j.rmed.2012.10.022. Epub 2012 Dec 6.


Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

Jones PW, Mahler DA, Gale R, Owen R, Kramer B.

Respir Med. 2011 Jun;105(6):892-9. doi: 10.1016/j.rmed.2011.02.013. Epub 2011 Mar 11.


Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.

Mahler DA, Buhl R, Lawrence D, McBryan D.

Pulm Pharmacol Ther. 2013 Jun;26(3):348-55. doi: 10.1016/j.pupt.2013.02.006. Epub 2013 Feb 19.


Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators.

Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62. doi: 10.1164/rccm.200910-1500OC. Epub 2010 May 12.


Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.

To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B.

Respir Med. 2012 Dec;106(12):1715-21. doi: 10.1016/j.rmed.2012.09.002. Epub 2012 Oct 5.


Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.

Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y; Indacaterol Asian COPD Study Investigators.

Respirology. 2012 Feb;17(2):379-89. doi: 10.1111/j.1440-1843.2011.02107.x.


Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.

Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP.

Value Health. 2012 May;15(3):524-33. doi: 10.1016/j.jval.2012.01.009. Epub 2012 Apr 11.


Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B; INTENSITY study investigators.

Eur Respir J. 2011 Oct;38(4):797-803. doi: 10.1183/09031936.00191810. Epub 2011 May 26.


The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.

Kerstjens HA, Deslée G, Dahl R, Donohue JF, Young D, Lawrence D, Kornmann O.

Pulm Pharmacol Ther. 2015 Jun;32:101-8. doi: 10.1016/j.pupt.2015.02.008. Epub 2015 Mar 3.


Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.

Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators.

Thorax. 2012 Sep;67(9):781-8. Epub 2012 Apr 27.


Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.

Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.

COPD. 2012 Dec;9(6):629-36. doi: 10.3109/15412555.2012.729623. Epub 2012 Sep 28.


Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.


Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.

Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V.

Respir Med. 2012 Jan;106(1):84-90. doi: 10.1016/j.rmed.2011.09.006. Epub 2011 Oct 27.


Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.

Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435.


Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.

Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.

Thorax. 2015 Apr;70(4):311-9. doi: 10.1136/thoraxjnl-2014-206345. Epub 2015 Feb 12.


Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S.

Thorax. 2003 May;58(5):399-404. Erratum in: Thorax. 2005 Feb;60(2):105.


Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.

Girodet PO, Jasnot JY, Le Gros V, Decuypère L, Cao W, Devouassoux G.

Respir Med. 2017 Jul;128:92-101. doi: 10.1016/j.rmed.2017.05.010. Epub 2017 May 24.


Supplemental Content

Support Center